Drug Profile
AM 211
Alternative Names: AM211Latest Information Update: 16 Mar 2016
Price :
$50
*
At a glance
- Originator Amira Pharmaceuticals
- Developer Panmira Pharmaceuticals
- Class Anti-inflammatories; Antiallergics; Small molecules
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Hypersensitivity
Most Recent Events
- 16 Mar 2016 No recent reports on development identified - Phase-I for Chronic obstructive pulmonary disease in USA (PO)
- 16 Mar 2016 No recent reports on development identified - Preclinical for Hypersensitivity in USA (PO)
- 16 Mar 2016 No recent reports on development identified - Phase-I for Asthma in USA (PO)